{
  "_id": "2a7e8efb00be16c80865ac3898af9c2351780649072550c7ae8758290afe49f1",
  "feed": "wall-street-journal",
  "title": "Merck Is in Advanced Talks to Buy Seagen; Deal could be worth roughly $40 billion or more",
  "text": "<p>Merck &amp; Co. is in advanced talks to acquire Seagen Inc. and is aiming to finalize a purchase of the cancer biotech in the next few weeks, according to people familiar with the matter, in a deal that could be worth roughly $40 billion or more.</p><p>The companies are discussing a price for Seagen above $200 a share and are seeking to seal a deal on or before the announcement of Merck's second fiscal-quarter earnings, set for July 28, the people said. Seagen's stock closed at $175.13 on Wednesday.</p><p>There is still no guarantee the companies will reach agreement on a takeover deal.</p><p>(More to Come)</p><p>Write to Cara Lombardo at cara.lombardo@wsj.com, Dana Cimilluca at dana.cimilluca@wsj.com and Jonathan D. Rockoff at Jonathan.Rockoff@wsj.com</p><p>Merck Is in Advanced Talks to Buy Seagen</p>",
  "published": "2022-07-07T02:27:00.000Z",
  "tags": [
    {
      "id": "US58933Y1055",
      "nexusId": "10042334",
      "name": "Merck & Co., Inc.",
      "offsets": [
        {
          "start": 0,
          "end": 11
        },
        {
          "start": 374,
          "end": 379
        },
        {
          "start": 0,
          "end": 5
        },
        {
          "start": 735,
          "end": 740
        }
      ]
    }
  ]
}